Author Archives: Patricia Inacio PhD

NIH Creates Huge Public-Private Partnership to Try to Speed Parkinson’s Therapy Development

The U.S. National Institutes of Health is starting a pioneering, multi-pronged public-private partnership program to try to accelerate the development of Parkinson’s treatments. What makes it special is how big it is. The NIH-led collaboration includes government, pharmaceutical companies, life science companies and non-profit organizations. The partners are calling the collaboration AMP…

Denali to Test Higher Doses of Potential Parkinson’s Therapy on Healthy Volunteers, With FDA’s Blessing

Denali Therapeutics says its experimental therapy for Parkinson’s disease, DNL201 — a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) — stopped an average 90 percent of LRRK2 kinase activity at its highest concentration. When the drug’s levels dropped to the lowest concentration (known as trough levels), it still inhibited…

Carbidopa Reduced Tumor Growth in Lab Studies of Cancer

Carbidopa, a medicine approved for the treatment of Parkinson’s disease, also has shown anti-cancer effects in lab-grown human cells and mice, according to the results of a new study. The findings help explain why cancer incidence usually is lower in Parkinson’s patients — with the exception of skin cancer — and…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums